FCH
HALO icon

Freestone Capital Holdings’s Halozyme HALO Stock Holding History

Freestone Capital Holdings’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-19,300
Closed -$146K – 330
2013
Q3 		$146K Buy
+19,300
New +$161K 0.03% 329

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Freestone Capital Holdings's HALO Position: Q4 2013 in Review

Freestone Capital Holdings sold out of Halozyme (HALO) in Q4 2013, closing a stake of 19,300 shares — an estimated $146K sold.

Freestone Capital Holdings first reported a position in HALO in Q3 2013 and held it in 1 quarter. The position peaked at $146K in Q3 2013. 119 funds tracked by Wall St. Rank hold HALO as of Q4 2013.

  • Freestone Capital Holdings reported no remaining Halozyme position as of Q4 2013 after selling out during the quarter.
  • Freestone Capital Holdings sold 19,300 Halozyme shares in Q4 2013, an estimated $146K.
  • Freestone Capital Holdings first reported a position in Halozyme in Q3 2013 and held it in 1 quarter.
  • Freestone Capital Holdings's Halozyme position peaked at $146K in Q3 2013.
  • 119 funds tracked by Wall St. Rank held Halozyme as of Q4 2013.

Based on Freestone Capital Holdings's 13F filing for Q4 2013, filed 13 Feb 2014.